胸腺法新对多发性骨髓瘤患者淋巴细胞亚群的影响研究OA

Objective To investigate the impact of thymalfasin on the immune system by detecting T/B/NK lymphocyte counts in peripheral blood of patients with multiple myeloma(MM).Methods A total of 40 MM patients who received first-line chemotherapy with bortezomib in the Department of Hematology of Loudi Central Hospital from June 2021 to June 2023 were selected.They were divided into the experimental group(n=15)and the control group(n=25)based on whether they received subcutaneous injections of 1.6 mg thymalfasin simultaneously.The values of T/B/NK lymphocyte subsets before and 2 weeks after chemotherapy were collected,and the differences in cell expression levels in and between the two groups were compared.Results The changes of T/B/NK lymphocytes before and after treatment in the control group were not statistically significant(P>0.05).The use of thymofaxine in the experimental group before and after treatment increased the absolute count of CD3+T lymphocytes,mainly in the percentage and absolute count of CD3+CD8+T lymphocytes,and the difference was statistically significant(P<0.05).Before treatment,the absolute counts of CD3+,CD3+CD4+and CD3+CD8+T lymphocytes in the test group were significantly lower than those in the control group,and the difference was statistically significant(P<0.05),and the percentages and absolute counts of CD19+B lymphocytes were lower than those in the control group,and the difference was statistically significant(P<0.05).After treatment,the CD19+B lymphocytes and CD3-CD16+/56+NK cells absolute counts were lower than those of the control group,and the difference was statistically significant(P<0.05).Conclusion The combined use of thymalfasin during treatment in MM patients can increase T lymphocyte counts,improve cellular immunity,and enhance anti-infection ability,which has clinical application value.